Publications by authors named "M Vrolix"
Background: The DynamX Novolimus-Eluting Coronary Bioadaptor System ( Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting.
Methods: This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had lesions in coronary arteries measuring between 2.
Article Synopsis
- The DynamX™ bioadaptor is a new coronary implant that unlocks its frame after 6 months, aiming to provide the benefits of drug-eluting stents while restoring vessel function.
- A trial involving 445 patients compared the bioadaptor to a zotarolimus-eluting stent across 34 hospitals in three countries, with an imaging subset for further assessment.
- The bioadaptor showed similar safety and success rates compared to stents at 12 months but demonstrated better effectiveness in reducing late lumen loss and improving vessel compliance.
BACKGROUND During transradial coronary angiography, when conventional J-tip wires fail to deliver catheters to the aortic root due to anatomical obstacles, additional hydrophilic wires, such as Radifocus (Terumo) or Silverway (Asahi), are used. We recently showed that the Silverway guidewire was effective at delivering the catheter to the aortic root. In this study, we aimed to compare the efficacy and safety of Radifocus and Silverway guidewires in 100 patients after failed use of the J-tip guidewire.
View Article and Find Full Text PDFArticle Synopsis
- European guidelines now recommend dual antithrombotic therapy (DAT) over triple antithrombotic therapy (TAT) for patients on oral anticoagulants undergoing coronary interventions, focusing on P2Y inhibitors and OAC without aspirin.
- The WOEST 2 registry was conducted to analyze the effectiveness and safety of these therapies in real-world settings, specifically looking at bleeding and thrombotic outcomes after one year.
- Results showed that DAT significantly reduced clinically relevant bleeding risks compared to TAT, while outcomes related to major adverse cardiac and cerebrovascular events were similar between both groups.
FFR pressure wire comparative study for drift: piezo resistive versus optical sensor.
Am J Cardiovasc Dis
February 2022
Background: This study aimed to assess the stability of pressure derived fractional flow reserve (FFR) measurement and the handling performance of the OptoWire Deux with an optical pressure sensor relative to the PressureWire X with piezo resistive pressure sensors.
Methods: This multicenter centre observational study included 50 patients between June 2017 and November 2018 undergoing a diagnostic coronary angiography with FFR measurement of moderate to severe lesions. The reliability of FFR measurement measured with the OptoWire Deux relative to the PressureWire X in each lesion was assessed by the presence of drift.